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Abstract
Diabetes is one of the leading causes of death in the United States and can cause severe impairments to
those diagnosed. Prediabetes is a state when a patient has higher fasting plasma glucose levels than a
non-diabetic person but is not quite high enough to be considered diabetes. Both diabetic and
prediabetic patients are at higher risk for cardiovascular diseases (CVD), which is the leading cause of
death in the United States. The primary form for prevention and treatment of CVD is through statin
therapy. Statins are a class of medications used to treat and prevent CVD by limiting cholesterol
production in the liver and stabilizing plaque in arteries. However, substantial research has found an
association between statin use and the development of Type 2 diabetes. This is an important association
to investigate because both statin use and diabetes are prevalent in the United States.
The association between statin use and the development of Type 2 diabetes poses a complicated risk for
prediabetic patients. Because they are already at high risk for diabetes, taking a statin could further
increase this risk. However, preventing CVD, which they are also at risk for, is critical as well. This
research investigates the relationship between statin use and prediabetic subjects specifically.
An adult, prediabetic subpopulation was obtained from the National Health and Nutrition Examination
Survey (NHANES), which is made publicly available through the Center for Disease Control and
Prevention. Several random forest classifiers were built using this subpopulation to predict statin use
among prediabetic patients. Analysis of the models found age, cholesterol levels, blood pressure levels,
waist size, body mass index (BMI), and annual household income to be the best predictors of statin use
in prediabetic subjects. Access to health insurance, gender, family history of heart attacks, and overall
health rating were found to be the least impactful predictors of statin use among prediabetic subjects in
all models. It appears the risk of CVD outweighs the risk of developing Type 2 diabetes, and doctors are
continuing to prescribe statins for prediabetic patients despite the increased risk of developing diabetes.
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1. Introduction
1.1 Background
Diabetes is the seventh-leading cause of death in the United States and affects over 30 million
Americans [1]. Type 1 diabetes occurs when the body does not make enough insulin and accounts for
5% of cases of diabetes [2]. This form of diabetes cannot be prevented. Type 2 diabetes is much more
common and is when the body cannot use insulin properly. Insulin is a hormone made by the pancreas
used to regulate blood sugar levels, which can lead to health complications if not properly controlled [3].
People who have diabetes can suffer from complications such as blindness, kidney failure, heart disease,
stroke, and loss of extremities [4].
Prediabetes is a state of latent impairment of carbohydrate metabolism in which the criteria for
diabetes are not all satisfied [5]. According to the American Diabetes Association (ADA), there are
approximately 3 million newly diagnosed prediabetes cases each year, and approximately 38% of adults
in the U.S. have prediabetes [6] . Most patients with prediabetes have impaired fasting glucose,
impaired glucose tolerance, metabolic syndrome, and high cholesterol levels. These conditions, along
with lifestyle choices, cause prediabetic patients to have a high risk of cardiovascular disease, similar to
patients with type 2 diabetes [7]. It is recommended pharmacological treatment be started to prevent
progression into type 2 diabetes.
Prediabetic and diabetic patients are at high risk for cardiovascular disease (CVD). CVD, which is
disease of the heart including diseased vessels, structural problems, and blood clots, is the leading cause
of death in the United States [8]. The primary form for prevention and treatment of CVD is through
statin therapy. Statins, one of the most widely prescribed types of medication in the United States, are a
class of medications used to prevent CVD by limiting cholesterol production in the liver and stabilizing
plaque in arteries [9]. Figure 1 shows the progression of cholesterol buildup progressively worsening
from left to right. The image on the right of the figure shows a blood clot, which can be deadly. Statins
can save lives by preventing this buildup.
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Figure 1. Healthy blood flow (left) progressing to a blood clot (right) as cholesterol builds up in arteries.

Unfortunately, substantial research has linked statin use with the development of Type 2
diabetes [10]. Figure 2 shows a clear difference between statin users (red) and non-statin users (blue) in
the percent of Type 2 diabetes instances in the respective populations. The study concluded being a
statin user was significantly associated with an increased risk of new onset diabetes [11]. Many other
research studies have reached the same conclusion. This is an important association to investigate
because both diabetes and statin use are so prevalent in the United States.

Figure 2. Comparison of percent of incident diabetes between statin users and non-users. [11]

The association between statin use and the development of Type 2 diabetes poses a
complicated risk for prediabetic patients. Because they are already at high risk for diabetes, taking a
statin could further increase this risk. However, preventing CVD, which they are also at risk for, is critical
as well. There are some cases where taking a statin might be worth it, and others where it may not.
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1.2 Literature Review
For years researchers have been investigating the association between statin use and new-onset
diabetes mellitus (NODM), which is when a subject with no previous history of diabetes develops and is
diagnosed with diabetes. A robust 2010 meta-analysis of over 90,000 subjects found statin therapy is
correlated with NODM, especially in older subjects [12]. This analysis also found the longer a subject had
been on statins, the more likely he or she was to develop NODM [12]. This study did not look at a
prediabetic population specifically.
A 2012 study examined statin risk along with cardiovascular outcomes in the general population.
The study found rates of diabetes were significantly higher in statin users (p < .001) over a median of 7.2
years [13]. However, major adverse cardiovascular events (MACE) and in-hospital mortality related to
cardiovascular events were less [13]. Through risk-benefit analysis, it was determined that statin
treatment was favorable in both high-risk and secondary treatment subjects in the general population
[13]. Secondary treatment is defined as “screening to identify diseases in the earliest stages, before the
onset of signs and symptoms, through measures such as mammography and regular blood pressure
testing” [14].
A post-hoc analysis of a clinical trial found subjects with one or more risk factors for diabetes
were at higher risk for NODM when subject to statin therapy than those with no major risk factors [15].
However, in individuals with one or more risk factors for diabetes, more adverse cardiovascular events
and deaths were avoided than new-onset cases of diabetes [15]. This suggests prediabetic subjects may
be at even higher risk for developing NODM than non-diabetic subjects. However, this risk may be worth
it considering the reduction in adverse cardiovascular events.
In 2012, the U.S. Food and Drug Administration updated their guidelines to add a safety warning
to statins indicating an increased risk for development of diabetes [16]. This change supports much of
the research done in this area; however, little research has been done to analyze prediabetic subjects
specifically. One study that did examine prediabetic subjects specifically found statin therapy is
associated with an increased risk in development of NODM [17]. Despite the risk of NODM, prediabetic
subjects would benefit from taking statins due to decreased risk of MACE and morbidity associated with
cardiovascular events [17].
While many studies have addressed the link between statin use and the onset of Type 2 diabetes,
research needs to be done specifically for high-risk patients like those with prediabetes. Little previous
research analyzes how the medical community is currently handling this dilemma. While the long-term
3

research goal is to develop a guideline on statin initiation for prediabetes patients, this research
analyzes the current practices with respect to statin use among prediabetes patients. We predict statin
use among a prediabetic population and analyze the resulting model to determine how this dilemma is
currently being handled.
The remainder of this thesis is organized as follows: Section 2 details the methodologies used to
reach our conclusions, including data collection and processing, data validation, and model
development. Section 3 states the results of the model, and Section 4 explains and draws conclusions
from these results.

2. Methodologies
This section summarizes research methodologies. Subsection 3.1 gives an overview of the National
Health and Nutrition Examination Survey (NHANES) data set, publicly available through the Center for
Disease Control and Prevention (CDC), and how specific sections of the data were selected and
processed for this research. Subsection 3.2 describes the extensive process of selecting and validating a
subpopulation of prediabetic patients. Subsection 3.3 details the algorithms and methods used to build
and train the model. Subsection 3.4 describes the methods used for model testing and validation.

2.1 Data Collection and Processing
NHANES is a survey of noninstitutionalized civilian residents of the United States population in their
homes with a laboratory component taking place in mobile examination centers. The questionnaire
portion of the survey ranges from weight history to smoking habits while the laboratory examination
tests for diseases, pregnancy, and, most importantly for this research, levels of different measures in the
body [18]. These measures include blood sugar levels, cholesterol levels, and insulin levels [18].
Participants are able to opt out of the laboratory examination if they choose to do so, and, for this
reason, there are fewer responses for the laboratory examination portion. Respondent personal
information, such as name and address, are not disclosed, and respondents are instead identified by a 5digit sequence number. This sequence number allows us to link participants’ responses from different
sections of the survey and from the laboratory examination. We have chosen to use the 2015-2016
survey data because it was the most recent published survey at the time this research started.
Because NHANES does not classify or categorize respondents in any way, we had to classify
prediabetic patients. There are various indicators commonly used by doctors to diagnose prediabetes
and diabetes including fasting plasma glucose (FPG) levels, the oral glucose tolerance test (OGTT), and
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hemoglobin A1C numbers. In the NHANES laboratory examination, FPG and OGTT were both taken.
Because healthcare professionals most commonly use FPG to diagnose prediabetes and diabetes, we
chose this test as our basis to classify respondents as “prediabetic”, “diabetic”, or “non-diabetic” [19].
Table 1, published by the American Diabetes Association (ADA), defines the criteria for prediabetes and
diabetes based on FPG.

Table 1. Summary table of prediabetes and diabetes classification standards [20].

The FPG test was completed by 2,972 respondents. Of these respondents, 1,227 were classified
as prediabetic. In the diabetes section of the survey, there is a question asking if a respondent has ever
been told they have diabetes by a doctor. Of those who responded “yes” to this question, 91 were a part
of the initial prediabetic subpopulation. Because these respondents had previously been diagnosed with
diabetes and were most likely treated for it, they were taken out of the subpopulation. Their treatment
for diabetes could be the reason they are now prediabetic by FPG level. Removing these respondents
brought the sample size down to 1,136. Finally, respondents under the age of 18 were removed.
Pediatric and adult diabetes are treated differently by the medical community and should be analyzed
separately. For this reason, we chose to focus on adult population. This subpopulation of 1,029 was used
for subsequent analysis. The process for arriving at the subpopulation is illustrated in Figure 3.

Figure 3. Process for arriving at final subpopulation for analysis.
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There is a question on the NHANES survey asking respondents if they have ever been told by a
doctor they have prediabetes. We chose not to use the answers to this question to define our
subpopulation because of the high number of missing responses and because patients may be
considered prediabetic even if they have not been diagnosed by a doctor. We did, however, use the
responses to this question for data validation, which will be discussed further in Section 3.2. The
demographic distributions of this final population are shown in Table 2.
Table 2. Distributions of demographics of final population.

Demographics Distributions
Gender

Male
55.00%

Female
45.00%

Age

18-29
13.90%

30-44
24.39%

Race/Ethnicity

Mexican American
18.76%

Household Size

1
14.38%

Annual Income

<20k
23.05%

Education

Less than 9th grade
13.08%

2
28.38%

45-59
25.85%

60-74
25.36%

Other Hispanic
13.31%
3
17.59%

4
15.84%

75+
10.50%
Non-Hispanic White
36.93%
5
10.59%

6
6.71%

Non-Hispanic Black
15.26%

Non-Hispanic Asian
12.05%

Other
3.69%

7+
6.51%

(20k,45k] (45k,65k] (65k,75k] (75k,100k] >100k
28.07%
16.22%
5.55%
10.99%
16.12%
9th-11th grade
12.07%

High School grad/GED Some college or AA College grad or above
22.33%
28.37%
24.14%

The response variable for the model is whether a prediabetic respondent is prescribed statins.
This response was determined using the “Prescription Medications” survey from the questionnaire
section. A question in this survey asked respondents to list all prescription medications they were taking
at the time of response. If one of the medications a respondent listed was a statin, they were given a “1”
as their response value. If they did not list a statin, they were given a “0” as their response value. There
was a question in the “Blood Pressure and Cholesterol” section asking if a respondent is prescribed
medicine for cholesterol, which is often a statin. The answer to this question was not used as the
response due to (1) a higher rate of missing values and (2) the “Prescription Medication” survey would
have been used to verify this cholesterol medication was a statin. The response to this question was
instead used for data validation, which will be discussed further in Section 3.2. 100% of the prediabetic
subpopulation responded to the prescription medication survey, so there was no missing response data.
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Eighteen predictors were chosen from various surveys in the questionnaire. Table 3 outlines
which survey each predictor is from and whether the predictor is demographic, health-related, or
behavioral. These categories will later be used to determine which types of factors are best at predicting
statin use. Predictors were chosen based on their potential to have a relationship with diabetes or
cholesterol levels. Age, gender, race, education, smoking, and family history of heart problems were
used to predict statin use in a study examining adults in the United States [21]. Predictors were also
chosen based on the quality of the data. Many survey questions had more than 25% of responses
missing and were therefore eliminated from consideration.

Table 3. Categorization of predictors chosen from NHANES.

Survey

Predictor

Type

Blood Pressure & Cholesterol

Has a doctor ever told you that you have high blood
pressure?
Has a doctor ever told you that you have high
cholesterol?
BMI
Waist size (cm)
Money spent on carryout food (past 30 days)

Health-related

Gender
Age (in years)
Household size
Annual family income
Education level
Race
Diet health rating (self-rating)
Number of fast food meals (past 30 days)
Number of ready-to-eat foods (past 30 days)

Demographic
Demographic
Demographic
Demographic
Demographic
Demographic
Behavioral
Behavioral
Behavioral

General Health

Health rating (self-rating)

Health-related

Health Insurance

Covered by Insurance

Demographic

Medical Conditions

Close relative had a heart attack

Health-related

Smoking – Cigarette Use

Smoke at least 100 cigarettes in life

Health-related

Body Measures
Consumer Behavior
Demographics

Diet and Nutrition

Health-related
Health-related
Health-related
Behavioral
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2.2 Data Validation
To determine which analysis techniques were the most appropriate for the data set, further
investigations were performed. A multicollinearity study was completed because many analysis
techniques assume independence, and if multicollinearity was present, some options would not be
appropriate. Each predictor was compared to the other 17 predictors to determine if there was a
significant relationship between the variables. Due to the categorical nature of the data, the Pearson
correlation coefficient could not be used to detect relationships between variables. Instead, a Chisquare test of independence was completed for each pair of predictors. A summary table of the results
can be found in the appendix. Based on a level of significance of .05, about 57% of the predictor pairs
had a significant relationship. In conclusion, the dataset exhibited strong multicollinearity. This makes
analyses that assume independence of predictor variables, such as regression analysis, inappropriate for
our model.
Most questions in the NHANES questionnaire were not completed by 100% of respondents. For
this reason, we had to handle missing data. The question used for the response variable, asking
respondents which prescriptions they were taking at the time of the questionnaire, was completed by all
respondents in our subpopulation. Handling missing data is especially important for the response
variable of a model, so it is fortunate this was the case. However, nine predictors, shown in Table 4, had
at least one observation missing.

Table 4. Predictors with at least one observation missing and their corresponding missing percentage.

Missing data was handled in three different ways: (1) treating missing as a category, (2)
implementing a k-nearest neighbor imputation, and (3) excluding all missing observations. Because the
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predictors are all categorical, it is appropriate to make missing its own category. This was done because
the fact the observation was missing could hold predictive power. In one version of the dataset, all null
values were replaced with a “-1” to indicate the variable was missing. Machine learning algorithms in
python will not run with null values, so the null values had to be mapped to a numerical value. Negative
one was chosen because no predictors take negative form.
The second approach to handling missing data was with a k-nearest neighbors (kNN) imputation.
kNN is an algorithm that takes the 𝑘 observations most similar to the observation with a missing value
and calculates the median or mean, depending on the type of variable, for the missing category [22].
This mean or median replaces the missing value. The value 𝑘 was chosen to be five because it is
relatively low, which increases the prevalence of local effects, and odd, which prevents ties for binary
predictors [22].
The third way of handling missing data was removing any observations with one or more values
missing in any category. To ensure this was an appropriate measure to take, we verified the data was
missing at random (MAR) [22]. We did this by comparing the distribution of the complete dataset with
the distribution of the missing-removed dataset for each predictor. An example is shown in Figure 5. If
the distributions look similar, it is fair to assume the data is missing at random. This was the case for all
18 predictors, making the missing-removed dataset valid.

Figure 4. BMI distributions for a) the complete dataset and b) the missing-removed dataset

Because the response variable is so critical, in addition to comparing the distributions, a twosample proportion test was completed. Because the response is binary, a proportion hypothesis test is
ideal. At the level of significance of 0.1, no significant difference was found between the complete
dataset and the missing-removed dataset. This also verifies the data is MAR because respondents who
left questions blank were not more likely to be prescribed a statin.
9

2.3 Model Development
The machine learning algorithm chosen for this model was a Random Forest Classifier (RFC). Due to the
presence of multicollinearity, discussed in Section 2.2, a model that assumes independence would be
inappropriate. The categorical nature of most of the predictors and binary nature of the response
variable were also factors in the selection of appropriate machine learning methods. For example,
because we know for certain which category the response should fall into (either taking statin or not
taking statin), a clustering algorithm such as k-means would not be appropriate. Algorithms requiring
very large amounts of data, such as neural networks, would also not be appropriate because the final
subpopulation included 1,029 observations. The ideal algorithm does not assume independence of
predictors, does not require very large data sets, and works well for classification (non-continuous)
responses. An RFC meets these requirements and therefore was used to create the models.
An RFC was created for each of the three ways of handling missing data, totaling in three
models. All categorical predictors were mapped to integer values so the Python algorithm could run
properly, and most were on an ordinal scale. This was the first step completed with each of the three
datasets.
After being prepared, the datasets were read into Python as a Pandas data frame. They were
then separated into two arrays: one for predictors and one for the response. These arrays were split into
a training set and a testing set. The training set contained 70% of the data, and the testing set contained
30%. The training set is used to build and fit the model, while the testing set is used to evaluate how
well the model is predicting. It is necessary to create both sets to properly evaluate a predictive model.
The RFC was built using a Random Forest Classifier method from the SciKit Learn library’s
“Ensemble” module [23]. The random state was set to 1, and 1,500 trees were used. Increasing the
number of trees improved prediction performance without taking too much time. Because RFCs are not
sensitive to overfitting, it was not a problem to use 17 predictors.

2.4 Model Testing
The testing set was used to evaluate model performance. For each algorithm built, the F1 score, percent
accuracy, and confusion matrix were output. An F1 score is a common metric for evaluating
classification algorithms that considers both precision and recall [24]. A confusion matrix is a 2x2 matrix
containing the frequencies of true positives, false positives, false negatives, and true negatives. The F1
score and confusion matrix were computed using SciKit Learn’s “Metrics” module. The percent accuracy
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was computed using a method in SciKit Learn’s “Ensemble” module. The results of these performance
metrics for each model are shown in Table 5.
F1 Score

Percent
Accuracy

Missing as category

0.495

83%

kNN imputation

.519

83%

Missing removed

0.51

86%

Model

Confusion
Matrix
[[230 20]
[33 26]]
[[229 21]
[ 31 28]]
[[135 5]
[20 13]]

Table 5. Model performance for each predictive model.

2.5 Subsequent Modeling
While RFCs can be great predictors, it is also common practice to use the importance information they
output for subsequent modeling. We used this approach in the feature subsect selection process for
further modeling. Cholesterol, blood pressure, age, waist size, and BMI were chosen to be used in
additional models because they were consistently important features across all RFC models.
We wanted to continue using classification models, so we decided to use a logistic regression,
which is a binary classification model. However, a simple logistic regression would not be sufficient on
its own due to presence of multicollinearity in the data. For this reason, regularization techniques were
used. Regularization techniques include penalty terms that penalize less important features so they do
not affect the outcome of the model as much as other features [25].
There are three common types of regularization methods: ridge, lasso, and elastic net. Ridge
regression can penalize features to make them less important, but they will never reach zero [25]. Lasso
regression is similar to ridge regression but can penalize features to zero and get rid of their information
completely [25]. Elastic net regression is a hybrid between ridge and lasso. It can perform similar to lasso
regressions but may perform better when features are highly correlated [26].
Features from the original dataset were all standardized to a 0 to 1 scale, and dummy variables
were created to represent the different age categories. Missing data was handled in only one way by
imputing the missing values. The package glmnet was then used in R to create the regularized
regressions [27]. The equation in Figure 5 shows how the penalty term is set up in this package. When
the parameter 𝛼 is set to 0, the lasso penalty disappears, and the model is a ridge regression. When 𝛼 is
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set to 1, the ridge penalty disappears, and the result is a lasso regression. An 𝛼 between 0 and 1 results
in an elastic net regression.

Figure 5. Demonstration of penalty term in glmnet package.

The confusion matrices and prediction accuracies for the three methods are shown in Figure 6.
Of the values tested, 𝛼=.5 was the best-performing elastic net regression. The elastic-net regression
performed the best for this data, and the ridge regression performed the worst. However, all models
performed pretty similarly.

Figure 6. Confusion matrices and accuracy of predictions for each type of regularized logistic regression.

3. Results
An RFC is a black box machine learning algorithm, meaning it is difficult to see what is happening
internally to cause the model to predict the way it is. For this reason, there are two ways to assess the
effects of the predictors. There is a high-level conclusion, which shows the importance of predictors
relative to each other. This is typically the more useful insight. There are also instance-level results,
which show how one specific observation was affected by each predictor to reach the predicted
response. This is not as useful because not as much insight can be gained from one specific instance. For
this reason, we focused on the relative importance of predictors (referred to as feature importance).
The relative importance of the first model, where missing was a category, is shown in Figure 7.
This model predicted with 83% accuracy. Generally, statin use was underpredicted. The model predicted
roughly 13% statin use while the real number is close to 17%. This could be due to statin use being the
minority response.
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Figure 7. Feature importance obtained by the RFC where missing was a category

The relative importance of the second model, where missing observations were removed, is
shown in Figure 8. This model predicted with 86% accuracy, making it more accurate than the previous
model. This model also underpredicted statin use. While the most important features are similar to the
previous model, they are not exactly the same. Age was a much more important feature when missing
values are removed. High blood pressure is much less important, moving from the third most important
feature to the eleventh. Waist size, BMI, and annual income are in similar positions. High cholesterol, as
expected, is still a very important feature despite not being the most important in the second model.
Whether a participant smokes changed from being one of the least important features in the previous
model the seventh most important feature in this model.
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Figure 8. Feature importance obtained by the RFC when observations with missing values are removed.

The relative feature importance of the third model, where missing values were imputed, is
shown in Figure 9. This model predicted with 83% accuracy, making it just as accurate as the first and
less accurate than the second. The relative feature importance order in this model was very similar to
the first. The top three features, high cholesterol, age, and high blood pressure, were the same. Waist
size, BMI, and annual income were also very important in the first model but in a different order.
Gender, insurance, and family heart attack history were the least important features in all three models.

Figure 9. Feature importance obtained by the RFC when missing values were imputed.
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4. Discussion and Conclusion
Among all three models, high cholesterol, age, BMI, waist size, annual income, and household size
seemed to be the best predictors of statin use in prediabetic patients. High cholesterol being a very
important feature in all models is intuitive because the U.S. Food and Drug Administration classifies
statins as a class of drugs used to treat high cholesterol [28]. A 2006 study found a positive correlation
between BMI and cholesterol in the general population; this could be a reason why BMI is fairly good
predictor of statin use [29]. A 1998 study found larger households are less likely to be on a lowcholesterol diet, perhaps contributing to why household size was a relatively important feature [30].
Meanwhile, gender, family history of heart attacks, and whether a patient had insurance were
the least impactful features. Aside from these three features, however, the order of the least impactful
predictors varied between models. We found the fact that insurance is among the least impactful
features in all three models surprising. Having medical insurance would seem to be a factor that would
make accessing statins easier; however, this does not appear to be the case among prediabetic patients.
One possible explanation for this is that statins are so important to patients they will ensure they have
the medication whether insured or not.
Another result we found surprising was the low ranking of smoking. A 1991 study of adults
found that cholesterol increased in both men and women for each cigarette smoked daily [31]. The U.S.
Food and Drug Administration describes statins as a drug used to lower cholesterol [28]. Because
smoking can raise cholesterol and statins can lower it, it would seem natural for them to have a
relationship; however, that does not appear to be the case in these models.
In Table 3 in Section 2.1, the features of the model were categorized as “Demographic,”
“Behavioral,” or “Health-related.” In general, health-related features such as blood pressure,
cholesterol, BMI, and waist size were of the highest importance. Behavioral features tended to be in the
15

middle of the importance ranking. Demographic characteristics were generally less important with age
and household size being exceptions.
Ideally, this research could be continued using data of the same patients over time to analyze
the new onset of diabetes in statin-using prediabetic patients specifically. The results of the analysis
could be used to determine which features are the most important in predicting whether a high-risk
patient using statins will develop new-onset diabetes. If these features differ from our findings of which
factors medical decision makers are currently taking into consideration when prescribing statins, this
could be cause for these decision makers to re-evaluate the criteria they use to make these decisions. In
this case we would have a baseline for current practices and an analysis determining which features
should be used in practice.
For future research on current practices specifically, we recommend investigating different
model types with different sets of features to try to improve model performance and including more
health-related features. It could be impactful to see how or if comorbidities affect statin initiation in
prediabetic patients. Oversampling methods could also be used in attempt to improve prediction
accuracy because the model is currently under-predicting statin use.
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5. Appendix
1) Results of Chi-square multicollinearity study
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